The estimated Net Worth of Adam S. Mostafa is at least $1.49 Million dollars as of 12 February 2024. Mr. Mostafa owns over 27,721 units of X4 Pharmaceuticals stock worth over $36,225 and over the last 5 years he sold XFOR stock worth over $585,442. In addition, he makes $866,231 as Chief Financial Officer and Treasurer at X4 Pharmaceuticals.
Sign up
Mr. Mostafa XFOR stock SEC Form 4 insiders trading
Adam has made over 19 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 52,500 units of XFOR stock worth $46,200 on 11 March 2024.
The largest trade he's ever made was selling 230,645 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $168,371. On average, Adam trades about 18,979 units every 52 days since 2019. As of 12 February 2024 he still owns at least 52,500 units of X4 Pharmaceuticals stock.
You can see the complete history of Mr. Mostafa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adam Mostafa biography
Adam S. Mostafa serves as Chief Financial Officer, Treasurer of the Company. He has served as X4’s Chief Financial Officer since September 2018. Prior to joining X4, Mr. Mostafa served as chief financial officer of Abpro Corporation, a biotechnology company focused on antibody therapeutics, from June 2016 to August 2018. Prior to that, Mr. Mostafa was a managing director in the healthcare investment banking group at Cantor Fitzgerald from January 2015 to May 2016, and from June 2011 to January 2015, Mr. Mostafa was a senior banker in the healthcare investment banking group at Needham & Company. Prior to that, Mr. Mostafa was a vice president in the investment banking group at CRT Capital Group from March 2007 to May 2011, and from September 2003 to March 2007, Mr. Mostafa was a portfolio management associate in the global stock selection group at AQR Capital. Mr. Mostafa began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University.
What is the salary of Adam Mostafa?
As the Chief Financial Officer and Treasurer of X4 Pharmaceuticals, the total compensation of Adam Mostafa at X4 Pharmaceuticals is $866,231. There are 1 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of $2,497,790.
How old is Adam Mostafa?
Adam Mostafa is 40, he's been the Chief Financial Officer and Treasurer of X4 Pharmaceuticals since 2019. There are 14 older and no younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.
What's Adam Mostafa's mailing address?
Adam's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.
Insiders trading at X4 Pharmaceuticals
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, and Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What does X4 Pharmaceuticals's logo look like?
Complete history of Mr. Mostafa stock trades at X4 Pharmaceuticals
X4 Pharmaceuticals executives and stock owners
X4 Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Paula Ragan,
President, Chief Executive Officer, Corporate Secretary, Director -
Adam Mostafa,
Chief Financial Officer, Treasurer -
Dr. Paula Ragan Ph.D.,
Founder, CEO, Pres, Sec. & Director -
Derek M. Meisner Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
Adam S. Mostafa,
CFO, Treasurer & Assistant Sec. -
Michael Wyzga,
Independent Chairman of the Board -
Gary Bridger,
Independent Director -
Murray Stewart,
Independent Director -
David McGirr,
Independent Director -
William Aliski,
Independent Director -
Rene Russo,
Director -
Candice Ellis,
Director, Corporate Communications & Investor Relations -
Alison Lawton,
Director -
Derek Meisner,
General Counsel -
Arthur Taveras,
Chief Scientific Officer -
Dr. Diego Cadavid M.D.,
Chief Medical Officer -
Carrie Melvin M.B.A.,
Sr. VP of Devel. Operations -
Dr. Robert David Arbeit,
Sr. VP of Clinical Devel. and Translational Research -
Ronny Mosston M.B.A.,
Sr. VP of HR -
Dr. Mary DiBiase Ph.D.,
Chief Operating Officer -
Keith Woods,
Director -
Craecker Francoise De,
Director -
Christophe Arbet Engels,
Chief Medical Officer -
Renato Skerlj,
Chief Scientific Officer -
Lynne E Kelley,
Chief Medical Officer -
Diego Cadavid,
Chief Medical Officer -
Mary Di Biase,
Chief Operating Officer